June 19, 2020

To,

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001
BSE Scrip code: 532531

The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Scrip Code: STAR

Dear Sirs,

Sub: Order of the National Company Law Tribunal, Bengaluru Bench sanctioning merger of wholly owned subsidiaries

This has reference to our earlier communication of July 29, 2019 relating to merger of Arrow Remedies Private Limited (“Arrow Remedies”), Fagris Medica Private Limited (“Fagris Medica”) and Strides Emerging Markets Limited (“SEML”) with the Company, which are direct/indirect wholly-owned subsidiaries of the Company.

We wish to inform that we have recently received the Order of the Bengaluru Bench of the National Company Law Tribunal, dated 28th May, 2020 (“Order”), which has sanctioned the petition filed by Strides Emerging Markets Limited for approval of the Scheme of Amalgamation of Arrow Remedies, Fagris Medica, SEML with Strides Pharma Science Limited (“SPSL”) and their respective shareholders and creditors (“Scheme”) pursuant to the provisions of Sections 230-232 and other applicable provisions of the Companies Act, 2013 (“the Act”).

The Appointed Date for the merger is April 1, 2019.

A joint petition for approval of the Scheme has been filed before the Mumbai Bench of the NCLT, since the registered offices of Arrow, Fagris and the Transferee Company are situated in Mumbai, Maharashtra.
It may please be noted that though the Bengaluru Bench of the NCLT has approved the Scheme, the approval from the Mumbai Bench of the NCLT is still pending and hence, the Scheme would be effective once it is approved by the Mumbai Bench of the NCLT and necessary post approval actions are completed in accordance with the Scheme and orders passed by the Bengaluru and the Mumbai Bench of the NCLT.

You are requested to take the same on record.

Thanks & Regards,
For Strides Pharma Science Limited

Manjula Ramamurthy
Company Secretary